游离DNA分析在癌症治疗中的应用
1. Haber DA, Velculescu VE. Blood-bad analys of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov 2014;4:650-661.
2. Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol 2017;14:531-548.
3. Alix-Panabières C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem 2013;59:110-118.
4. Ruivo CF, Adem B, Silva M, Melo SA. The biology of cancer exosomes: insights and new perspectives. Cancer Res 2017;77:6480-6488.
消失的反义词是什么5. Schwarzenbach H, Nishida N, Calin GA, Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol 2014;11:145-156.
6. Husain H, Melnikova VO, Kosco K, et al. Monitoring daily dynamics of early tumor respon
to targeted therapy by detecting circulating tumor DNA in urine. Clin Cancer Res 2017;23:4716-4723.
滨水学校
7. Wang Y, Springer S, Mulvey CL, et al. Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Sci Transl Med 2015;7:293ra104-293ra104.
脂肪是怎么形成的8. De Mattos-Arruda L, Mayor R, Ng CK, et al. Cerebrospinal fluid-derived circulating tumour DNA better reprents the genomic alterations of brain tumours than plasma. Nat Commun 2015;6:8839-8839.
长大作文9. Mandel P, Metais P. Les acides nucléiques du plasma sanguin chez l’homme. C R Seances Soc Biol Fil 1948;142:241-243.
10. Fan HC, Blumenfeld YJ, Chitkara U, Hudgins L, Quake SR. Analysis of the size distributions of fetal and maternal cell-free DNA by paired-end quencing. Clin Chem 2010;56:1279-1286.
微信怎样转账
11. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the rum of cancer patients and the effect of therapy. Cancer Res 1977;37:646-650.
12. Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to asss tumor dynamics. Nat Med 2008;14:985-990.
13. Bettegowda C, Saun M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014;6:224ra24-224ra24.
14. El Messaoudi S, Rolet F, Mouliere F, Thierry AR. Circulating cell free DNA: preanalytical considerations. Clin Chim Acta 2013;424:222-230.
15. Swinkels DW, Wiegerinck E, Steegers EA, de Kok JB. Effects of blood-processing protocols on cell-free DNA quantification in plasma. Clin Chem 2003;49:525-526.
16. Alidousty C, Brandes D, Heydt C, et al. Comparison of blood collection tubes from three different manufacturers for the collection of cell-free DNA for liquid biopsy mutation testing. J Mol Diagn 2017;19:801-804.
17. Diehl F, Li M, He Y, Kinzler KW, Vogelstein B, Dressman D. BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat Methods 2006;3:551-559.
18. Hindson BJ, Ness KD, Masquelier DA, et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem 2011;83:8604-8610.
19. Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep quencing of plasma DNA. Sci Transl Med 2012;4:136ra68-136ra68.
20. Adalsteinsson VA, Ha G, Freeman SS, et al. Scalable whole-exome quencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun 2017;8:1324-1324.
21. Leary RJ, Kinde I, Diehl F, et al. Development of personalized tumor biomarkers using massively parallel quencing. Sci Transl Med 2010;2:20ra14-20ra14.
22. Murtaza M, Dawson SJ, Tsui DW, et al. Non-invasive analysis of acquired resistance t
古代文学家o cancer therapy by quencing of plasma DNA. Nature 2013;497:108-112.
保理业务是什么
23. Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B. Detection and quantification of rare mutations with massively parallel quencing. Proc Natl Acad Sci U S A 2011;108:9530-9535.
24. Newman AM, Bratman SV, To J, et al. An ultransitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 2014;20:548-554.
25. Newman AM, Lovejoy AF, Klass DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol 2016;34:547-555.
茶杯蛋糕26. Garraway LA, Jänne PA. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov 2012;2:214-226.
27. Kuderer NM, Burton KA, Blau S, et al. Comparison of 2 commercially available next-generation quencing platforms in oncology. JAMA Oncol 2017;3:996-998.
28. Chae YK, Davis AA, Carneiro BA, et al. Concordance between genomic alterations assd by next-generation quencing in tumor tissue or circulating cell-free DNA. Oncotarget 2016;7:65364-65373.